Recycling Polycarbonyl Redox Therapy


  • This class of novel proprietary compounds represents a new platform of investigational drug candidates.

  • By driving mitochondrial metabolism, RPRx induces a recycling redox mechanism in abnormally proliferating or disabled cells until normal signaling mechanisms are restored.

  • This process either leads to metabolism of intracellular debris and prenylated cross-linkages (fixing the diseased cell) or drives diseased cell to apoptosis (programmed cell death).

  • Healthy cells have enzymatic mechanisms that prevent over expression of the RPRx mechanism of action.

  • Thus, the core mechanism of action selectively targets diseased cells, rather than healthy cells.



Results from Anecdotal animal studies


Equine Myeloencephalitis (EPM)

•  311 horses treated with intravenous administration of this class of compounds.

•  296 horses (95%) asymptomatic within 7-14 days.

Equine Melanoma

•  Mode of mechanism suggests apoptosis of neoplastic tissue (without necrosis)

•  6 of 6 horses completely resolved with no complications.

Johne’s Disease: Chronic Inflammation

• 2 of 2 bulls resolved with no complications.